版本:
中国

BRIEF-EU Medicines Agency recommendations for April 2017

April 21 EU Medicines Agency -

* EU Medicines Agency recommendations for April 2017

* EU Medicines Agency recommends approval granting of a marketing authorisation for Sandoz's Rixathon Non-Hodgkin's Lymphoma (NHL), chronic lymphocytic leukaemia

* Recommends approval of Sanofi SA and Regeneron's Kevzara (Sarilumab) for treatment of rheumatoid arthritis

* Recommends approval of Biogen Spinraza drug for spinal muscular atrophy drug

* Recommends approval of Pfizer's Besponsa for treatment of acute lymphoblastic leukaemia

* Recommends approval of Biomarin Neuronal Ceroid Lipofuscinosis drug

* Recommends approval of GMP-Orphan SA's Cuprior for treatment of Wilson's disease

* Recommends approval of Almirall's Skilarence for treatment of psoriasis

* Recommends approval of Mylan S.A.S' Febuxostat Mylan for prevention and treatment of hyperuricaemia Source text - bit.ly/2oulvdj (Bengaluru Newsroom)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐